Environmental study analyzing the knowledge of vaccinated patients about complications after vaccination against COVID-19: A preliminary report

• Authors: Maria Stachura , Adriana Biela , Zuzanna Puszczewicz , Julia Wypyszyńska , Natalia Zaboklicka , Tomasz Męcik-Kronenberg

Title variants

PL

Badanie środowiskowe analizujące wiedzę zaszczepionych pacjentów na temat powikłań po szczepieniu przeciwko COVID-19 – doniesienie wstępne

• Languages of publication: EN PL

Abstracts

EN

INTRODUCTION: The aim of this study is to analyze the knowledge of vaccinated Poles about the side effects of COVID-19 vaccination in the light of misinformation about vaccines, their mechanism, and complications. MATERIAL AND METHODS: The authors created an anonymous online survey. The study group consisted of 2,345 people and included 1,468 people vaccinated against COVID-19. RESULTS: Vaccine leaflets, social media, and doctors were listed as the most frequent sources of information about vaccines. When asked about the possibility of developing COVID-19 as a result of vaccination, 55.18% of the respondents answered that it is not possible. Only 2.72% of the respondents claimed that complications will occur after each vaccine and booster dose. According to the respondents, the most common complication following the Comirnaty vaccine is muscle pain; after the Vaxzevria vaccine it is fever. In the case of the Moderna and Janssen vaccines, most did not know the answer. CONCLUSIONS: The respondents knew the most about the side effects related to the Comirnaty vaccine and the least about the Janssen and Moderna ones. In the case of the Vaxzevria vaccine, the respondents pointed to thromboembolic events as one of the most common complications. The most common source of information was the vaccine leaflet. Fears about complications were declared by the highest number of people vaccinated with the Janssen vaccine.

PL

WPROWADZENIE: Celem niniejszego badania jest analiza wiedzy zaszczepionych Polaków na temat powikłań po szczepieniu przeciwko COVID-19 w obliczu konieczności zwiększenia wiedzy na temat szczepionek, mechanizmu ich działania oraz powikłań. MATERIAŁ I METODY: Autorzy stworzyli anonimową ankietę internetową. Badana populacja liczyła 2345 osób, w tym 1468 zaszczepionych przeciwko COVID-19. WYNIKI: Jako najczęstsze źródła informacji o szczepionkach wskazywano ulotkę szczepionki, media społecznościowe oraz lekarza. Na pytanie o możliwość zachorowania na COVID-19 w wyniku szczepienia 55,18% respondentów odpowiedziało przecząco. Jedynie 2,72% ankietowanych twierdziło, iż po każdej dawce szczepionki wystąpią powikłania. Zdaniem ankietowanych najczęstszym powikłaniem po szczepionce Comirnaty jest ból mięśni, a po szczepionce Vaxzevria gorączka. W przypadku szczepionek Moderna i Janssen większość nie znała odpowiedzi. WNIOSKI: Ankietowani wiedzieli najwięcej o powikłaniach mogących wystąpić po przyjęciu szczepionki Comirnaty, a najmniej o powikłaniach po szczepionkach Janssen i Moderna. W przypadku szczepionki Vaxzevria jako jedno z najczęstszych powikłań ankietowani wskazali incydenty zakrzepowo-zatorowe. Najczęstszym źródłem informacji o powikłaniach była ulotka dołączona do szczepionki. Obawy przed powikłaniami deklarowała największa liczba osób zaszczepionych szczepionką Janssen.

Keywords

EN

COVID-19; SARS-CoV-2; szczepionka; vaccine

Discipline

• MEDICINE: MEDICINE

• Publisher: Śląski Uniwersytet Medyczny w Katowicach
• Journal: Annales Academiae Medicae Silesiensis
• Year: 2025
• Volume: 79
• Pages: 368–378

Contributors

author

Maria Stachura

• Students’ Scientific Club, Department of Pathomorphology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

author

Adriana Biela

• Students’ Scientific Club, Department of Pathomorphology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

author

Zuzanna Puszczewicz

• Students’ Scientific Club, Department of Pathomorphology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

author

Julia Wypyszyńska

• Students’ Scientific Club, Department of Pathomorphology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

author

Natalia Zaboklicka

• Students’ Scientific Club, Department of Pathomorphology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

author

Tomasz Męcik-Kronenberg

• Department of Pathomorphology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

References

• 1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497–506, doi: 10.1016/S0140-6736(20)30183-5.
• 2. Listings of WHO’s response to COVID-19. World Health Organization, 29 June 2020 [online] https://www.who.int/news/item/29-06-2020-covidtime-line [accessed on 7 September 2022].
• 3. Khan M., Adil S.F., Alkhathlan H.Z., Tahir M.N., Saif S., Khan M. et al. COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far. Molecules. 2020;26(1):39. doi: 10.3390/molecules26010039.
• 4. Pierwszy przypadek koronawirusa w Polsce. Gov.pl – Serwis Rzeczypospolitej Polskiej / Ministerstwo Zdrowia, 04.03.2020 [online] https://www.gov.pl/web/zdrowie/pierwszy-przypadek-koronawirusa-w-polsce [accessed on 7 September 2022].
• 5. Habas K., Nganwuchu C., Shahzad F., Gopalan R., Haque M., Rahman S. et al. Resolution of coronavirus disease 2019 (COVID-19). Expert Rev. Anti Infect Ther. 2020;18(12):1201-1211, doi: 10.1080/14787210.2020.1797487.
• 6. Tianyu Z., Liying G. Identifying the molecular targets and mechanisms of xuebijing injection for the treatment of COVID-19 via network pharmacology and molecular docking. Bioengineered. 2021; 12(1): 2274–2287, doi: 10.1080/21655979.2021.1933301.
• 7. Wadaa-Allah A., Emhamed M.S., Sadeq M.A., Ben Hadj Dahman N., Ullah I., Farrag N.S. et al. Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review. Ann. Med. 2021; 53(1): 318–334, doi: 10.1080/07853890.2021.1875500.
• 8. Christie A., Henley S.J, Mattocks L., Fernando R., Lansky A., Ahmad F.B. et al. Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine – United States, September 6, 2020–May 1, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(23): 858–864, doi: 10.15585/mmwr.mm7023e2.
• 9. Sansone E., Sala E., Tiraboschi M., Albini E., Lombardo M., Indelicato A. et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 among healthcare workers. Med Lav. 2021;112(3):250-255. doi: 10.23749/mdl.v112i3.11747.
• 10. Meyer E.D., Sandfort M., Bender J., Matysiak-Klose D., Dörre A., Bojara G. et al. Two doses of the mRNA BNT162b2 vaccine reduce severe outcomes, viral load and secondary attack rate: evidence from a SARS-CoV-2 Alpha outbreak in a nursing home in Germany, January-March 2021. medRxiv. 2021, doi: 10.1101/2021.09.13.21262519.
• 11. Levine-Tiefenbrun M., Yelin I., Katz R., Herzel E., Golan Z., Schreiber L. et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021;27(5):790-792. doi: 10.1038/s41591-021-01316-7.
• 12. The Visual and Data Journalism Team / BBC News. Covid vaccines: How fast is progress around the world? BBC, 1 June 2022 [online] https://www.bbc.com/news/world-56237778 [accessed on 7 September 2022].
• 13. Sallam M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates. Vaccines. 2021; 9(2): 160, doi: 10.3390/vaccines9020160.
• 14. Shakespeare gets Covid vaccine: All's well that ends well. BBC, 8 December 2020 [online] https://www.bbc.com/news/uk-55233021 [accessed on 7 September 2022].
• 15. Over 40 million people receive first dose of COVID-19 vaccine in UK. Gov.uk, 5 June 2021 [online] https://www.gov.uk/government/news/over-40-million-people-receive-first-dose-of-covid-19-vaccine-in-uk [accessed on 19 October 2021].
• 16. W Polsce ruszyły szczepienia przeciw COVID-19 – „to historyczny moment”. Szczepienia.Info, 30 grudnia 2020 [online] https://szczepienia.pzh.gov.pl/w-polsce-ruszyly-szczepienia-przeciw-covid-19-to-historyczny-moment/ [accessed on 19 October 2021].
• 17. Mathieu E., Ritchie H., Rodés-Guirao L., Appel C., Gavrilov D., Giattino C. et al. Coronavirus (COVID-19) Vaccinations – Statistics and Research. Our World in Data, 2020 [online] https://ourworldindata.org/covid-vaccinations [accessed on 29 March 2022].
• 18. Dawka przypominająca. Gov.pl – Serwis Rzeczypospolitej Polskiej / Ministerstwo Zdrowia [online] https://www.gov.pl/web/szczepimysie/trzecia-dawka [accessed on 7 September 2022].
• 19. Raport szczepień przeciwko COVID-19. Gov.pl – Serwis Rzeczypospolitej Polskiej / Ministerstwo Zdrowia [online] –https://www.gov.pl/web/szczepimysie/raport-szczepien-przeciwko-covid-19 [accessed on 29 March 2022].
• 20. Narodowy Program Szczepień przeciw COVID-19. Gov.pl – Serwis Rzeczypospolitej Polskiej [online] https://www.gov.pl/web/szczepimysie/narodowy-program-szczepien-przeciw-covid-19 [accessed on 7 September 2022].
• 21. Hajissa K., Mussa A. Positive aspects of the mRNA platform for SARS-CoV-2 vaccines. Hum Vaccin Immunother. 2021; 17(8): 2445–2447, doi: 10.1080/21645515.2021.1900713.
• 22. Zhang N.N., Li X.F., Deng Y.Q., Zhao H., Huang Y.J., Yang G. et al. A Thermostable mRNA Vaccine against COVID-19. Cell. 2020; 182(5): 1271–1283.e16, doi: 10.1016/j.cell.2020.07.024.
• 23. Bettini E., Locci M. SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines. 2021; 9(2): 147, doi: 10.3390/vaccines9020147.
• 24. Podsumowanie – Szczepionka przeciw COVID-19. Szczepienia.Info [online] https://szczepienia.pzh.gov.pl/szczepionki/covid-19-2/ [accessed on 29 March 2022].
• 25. Dong Y., Dai T., Wei Y., Zhang L., Zheng M., Zhou F. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020; 5(1): 237, doi: 10.1038/s41392-020-00352-y.
• 26. Pytania i odpowiedzi na temat szczepionek przeciwko COVID-19 w UE. Komisja Europejska [online] https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/safe-covid-19-vaccines-europeans/questions-and-answers-covid-19-vaccination-eu_pl#vaccination [accessed on 29 March 2022].
• 27. Jarynowski A., Skawina I. Attempt at profiling and regionalisation of COVID-19 vaccine campaigns in Poland – preliminary results. Eur. J. Transl. Clin. Med. 2021; 4(1): 13–21, doi: 10.31373/ejtcm/134674.
• 28. State of Vaccine Confidence in EU, 2018. Vaccine Confidence Project online https://www.vaccineconfidence.org/research-feed/the-state-of-vaccine-confidence-in-the-eu-2018 [accessed on 19 October 2021].
• 29. Etapy rozwoju człowieka – dorosłość. EDULIDER.pl [online] https://www.edulider.pl/edukacja/etapy-rozwoju-czlowieka-doroslosc [accessed on 19 October 2021].
• 30. Chou W.S., Budenz A. Considering Emotion in COVID-19 Vaccine Communication: Addressing Vaccine Hesitancy and Fostering Vaccine Confidence. Health Commun. 2020; 35(14): 1718–1722, doi: 10.1080/10410236.2020.1838096.
• 31. Menni C., Klaser K., May A., Polidori L., Capdevila J., Louca P. et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021; 21(7): 939–949, doi: 10.1016/S1473-3099(21)00224-3.
• 32. Riad A., Hocková B., Kantorová L., Slávik R., Spurná L., Stebel A. et al. Side Effects of mRNA-Based COVID-19 Vaccine: Nationwide Phase IV Study among Healthcare Workers in Slovakia. Pharmaceuticals. 2021; 14(9): 873, doi: 10.3390/ph14090873.
• 33. Klugar M., Riad A., Mekhemar M., Conrad J., Buchbender M., Howaldt H.P. et al. Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers. Biology. 2021; 10(8): 752, doi: 10.3390/biology10080752.
• 34. Riad A., Pokorná A., Attia S., Klugarowá J., Koščík M., Klugar M. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. J. Clin. Med. 2021; 10(7): 1428, doi: 10.3390/jcm10071428.
• 35. Comirnaty: COVID-19 mRNA vaccine / Product Information [Comirnaty: EPAR – Product information; annex IIIB]. European Medicines Agency [online] https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty [accessed on 7 September 2022].
• 36. Niepożądane odczyny poszczepienne po szczepionkach przeciw COVID-19 w Polsce: Raport za okres 27.12.2020–26.04.2021. Narodowy Instytut Zdrowia Publicznego – Państwowy Zakład Higieny [online] https://www.pzh.gov.pl/serwisy-tematyczne/niepozadane-odczyny-poszczepienne-covid-19/ [accessed on 19 October 2021].
• 37. 27.12.2020-07.10.2021 – bieżący raport dot. NOP [pdf]. [Accessed on website]: Gov.pl – Serwis Rzeczypospolitej Polskiej [online] https://www.gov.pl/web/szczepimysie/niepozadane-odczyny-poszczepienne [accessed on 19 October 2021].
• 38. COVID-19 Vaccine Moderna: COVID-19 mRNA vaccine / Product Information. European Medicines Agency [online] https://ec.europa.eu/health/documents/community-register/2021/20210106150575/anx_150575_pl.pdf [accessed on 7 Se-ptember 2022].
• 39. COVID-19 Vaccine Janssen: EPAR – Product Information. Ulotka dla pacjenta. Europejska Agencja Leków [online] https://ec.europa.eu/health/documents/community-register/2021/20210311151284/anx_151284_pl.pdf [accessed on 7 September 2022].
• 40. COVID-19 Vaccine AstraZeneca: EPAR – Product Information. Ulotka dla pacjenta. Europejska Agencja Leków [online] https://ec.europa.eu/health/documents/community-register/2021/20210129150842/anx_150842_pl.pdf [accessed on 7 September 2022].
• 41. Schulz J.B., Berlit P., Diener H.C., Gerloff C., Greinacher A., Klein C. et al. COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany. Ann. Neurol. 2021; 90(4): 627–639,. doi: 10.1002/ana.26172.
• 42. Hunter P.R. Thrombosis after covid-19 vaccination. BMJ. 2021; 373: n958, doi: 10.1136/bmj.n958.
• 43. Hippisley-Cox J., Patone M., Mei X.W., Saatci D., Dixon S., Khunti K., et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ. 2021; 374: n1931, doi: 10.1136/bmj.n1931.
• 44. COVID-19. Centers for Disease Control and Prevention [online] https://www.cdc.gov/coronavirus/2019-ncov/vaccines/facts.html [accessed on 19 October 2021].
• 45. Sokolowska M., Eiwegger T., Ollert M., Torres M.J., Barber D., Del Giacco S. et al. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Allergy. 2021; 76(6): 1629–1639, doi: 10.1111/all.14739.
• 46. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine – United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep. 2021; 70(2): 46–51, doi: 10.15585/mmwr.mm7002e1.

• Document Type: article